Synta Pharmaceuticals Corp.
45 Hartwell Avenue
Lexington,
MA 02421
United States - Map
Phone: 781-274-8200
Fax: 781-274-8228
Web Site: http://www.syntapharma.com
| Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Safi R. Bahcall Ph.D., 40
Co-Founder, Chief Exec. Officer, Pres |
N/A
| N/A | Dr. Lan Bo Chen Ph.D., 65
Co-Founder |
N/A
| N/A | Mr. Keith Ehrlich C.P.A., 58
Chief Financial Officer, Principal Accounting Officer, VP of Admin. & Fin. |
N/A
| N/A | Dr. Keizo Koya Ph.D., 51
Sr. VP of Drug Devel. |
N/A
| N/A | Dr. James G. Barsoum Ph.D., 52
Sr. VP of Research |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 0.00%
Profile
